|
SuFEx (Sulfur-Fluoride Exchange) Chemistry represents the next-generation approach to covalent drug discovery, chemical biology, and synthetic chemistry. Building on the principles of click chemistry, SuFEx reactions leverage the unique S(VI)–F bond, allowing precise and high-yielding chemical transformations under mild conditions.
OTAVA, in collaboration with Melius Organics, introduces a comprehensive SuFEx Handle Fragment Library, a diverse collection of aryl fluorosulfates and sulfamoyl fluorides designed to expand the druggable proteome, enhance covalent drug development, and facilitate advanced chemical synthesis.
|
|
Read more...
|
|
CHEMriya™ is an ultra-large combinatorial Chemical Space developed by OTAVA to transform hit expansion, hit-to-lead optimization, and compound evolution. Designed to accelerate drug discovery, CHEMriya provides access to a vast collection of chemically diverse molecules for pharmaceutical research and computational screening.
Explore CHEMriya on BioSolveIT
|
|
Read more...
|
|
 The interaction of proteins are critical to nearly all biological processes, including cellular signaling [1]. We offer special screening Peptidomimetic Libraries: β-Turn Peptidomimetic Library containing synthetic compounds which mimic beta-turns of proteins and a-Helix Peptidomimetic Library of compounds mimic alpha-helixes of proteins. These libraries are intended for research and drug discovery projects focused on protein-protein interactions.
|
|
Read more...
|
|
|
 UPDATED! The library has been just updated!
The central purpose of this specially designed Fragment Library is to provide
|
|
Read more...
|
|
Tissue transglutaminase 2 (tTG2) is a multifunctional enzyme involved in extracellular matrix stabilization, cell adhesion, signal transduction, and protein crosslinking. It plays a pivotal role in various physiological processes, but its dysregulation has been implicated in multiple diseases, including celiac disease, fibrosis, cancer, and neurodegenerative disorders. Due to its involvement in disease progression, tTG2 is a prime target for drug discovery, yet the development of small-molecule inhibitors remains an underexplored frontier.
|
|
Read more...
|
|
|
|
|
|
|
Page 4 of 15 |
HOME
Overview
